Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience

BACKGROUND: Following the approval of bezlotoxumab in 2017, studies evaluating its effectiveness in prevention of Clostridioides difficile infection under “real-life” conditions are scarce. MATERIAL AND METHODS: We conducted a retrospective study developed in a large tertiary care hospital describin...

Descripción completa

Detalles Bibliográficos
Autores principales: Olmedo, María, Kestler, Marta, Valerio, Maricela, Padilla, Belén, González, Carmen Rodríguez, Chamorro, Esther, Machado, Marina, Alvarez-Uría, Ana, Alcalá, Luis, Muñoz, Patricia, Bouza, Emilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Quimioterapia 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134882/
https://www.ncbi.nlm.nih.gov/pubmed/35279984
http://dx.doi.org/10.37201/req/120.2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134882/
https://www.ncbi.nlm.nih.gov/pubmed/35279984
http://dx.doi.org/10.37201/req/120.2021

Ejemplares similares